Improvement of skeletal muscle performance in ageing by the metabolic modulator Trimetazidine

Journal of Cachexia, Sarcopenia and Muscle

Volumn 7, Issue 4, 2016, Pages 449-457

  Ferraro, Elisabetta ^a   Pin, Fabrizio ^b,c   Gorini, Stefania ^a   Pontecorvo, Laura ^a   Ferri, Alberto ^d   Mollace, Vincenzo ^e   Costelli, Paola ^b,c   Rosano, Giuseppe ^a,f  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c Istituto Interuniversitario di Miologia IIM   (Italy)

^d CNR   (Italy)

^e UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^f ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Aging, Exercise pill; Metabolic reprogramming; Neuro rehabilitation; Sarcopenia

Indexed keywords

ACETYL COENZYME A; ALPHA TUBULIN; DESMIN; FATTY ACID; GLUCOSE; LAMININ; MYHC PROTEIN; MYOSIN HEAVY CHAIN; STRUCTURAL PROTEIN; TRIMETAZIDINE; UNCLASSIFIED DRUG;

AGED; AGING; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FALLING; GASTROCNEMIUS MUSCLE; GLUCOSE BLOOD LEVEL; GRIP STRENGTH; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; MUSCLE ATROPHY; MUSCLE CELL; MUSCLE FUNCTION; MUSCLE MASS; MUSCLE METABOLISM; MUSCLE STRENGTH; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKELETAL MUSCLE; TIBIALIS ANTERIOR MUSCLE; WESTERN BLOTTING;

EID: 84953320859     PISSN: 21905991     EISSN: 21906009     Source Type: Journal    
DOI: 10.1002/jcsm.12097     Document Type: Article

References (50)

1. Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell 2013;153:1194–1217.
2. Forte R, Pesce C, Leite JC, De Vito G, Gibney ER, Tomporowski PD, et al. Executive function moderates the role of muscular fitness in determining functional mobility in older adults. Aging Clin Exp Res 2013;25:291–298.
3. Rao SS. Prevention of falls in older patients. Am Fam Physician 2005;72:81–88.
4. Janssen I, Baumgartner RN, Ross R, Rosenberg IH, Roubenoff R. Skeletal muscle cutpoints associated with elevated physical disability risk in older men and women. Am J Epidemiol 2004;159:413–421.
5. von Haehling S, Morley JE, Anker SD. From muscle wasting to sarcopenia and myopenia: update 2012. J Cachexia Sarcopenia Muscle 2012;3:213–217.
6. Baumgartner RN. Body composition in healthy aging. Ann N Y Acad Sci 2000;904:437–448.
7. Snijders T, Verdijk LB, van Loon LJ. The impact of sarcopenia and exercise training on skeletal muscle satellite cells. Ageing Res Rev 2009;8:328–338.
8. Lexell J, Taylor CC, Sjostrom M. What is the cause of the ageing atrophy? Total number, size and proportion of different fiber types studied in whole vastus lateralis muscle from 15- to 83-year-old men. J Neurol Sci 1988;84:275–294.
9. Narici MV, Maffulli N. Sarcopenia: characteristics, mechanisms and functional significance. Br Med Bull 2010;95:139–159.
10. Volpi E, Sheffield-Moore M, Rasmussen BB, Wolfe RR. Basal muscle amino acid kinetics and protein synthesis in healthy young and older men. JAMA 2001;286:1206–1212.
11. Fry CS, Rasmussen BB. Skeletal muscle protein balance and metabolism in the elderly. Curr Aging Sci 2011;4:260–268.
12. Lang T, Streeper T, Cawthon P, Baldwin K, Taaffe DR, Harris TB. Sarcopenia: etiology, clinical consequences, intervention, and assessment. Osteoporosis Int 2010;21:543–559.
13. Carlson ME, Suetta C, Conboy MJ, Aagaard P, Mackey A, Kjaer M, et al. Molecular aging and rejuvenation of human muscle stem cells. EMBO Mol Med 2009;1:381–391.
14. Kadi F, Charifi N, Denis C, Lexell J. Satellite cells and myonuclei in young and elderly women and men. Muscle Nerve 2004;29:120–127.
15. Conboy IM, Conboy MJ, Smythe GM, Rando TA. Notch-mediated restoration of regenerative potential to aged muscle. Science 2003;302:1575–1577.
16. Roubenoff R. Physical activity, inflammation, and muscle loss. Nutr Rev 2007;65:S208–S212.
17. Neels JG, Olefsky JM. Inflamed fat: what starts the fire? J Clin Invest 2006;116:33–35.
18. Jang YC, Lustgarten MS, Liu Y, Muller FL, Bhattacharya A, Liang H, et al. Increased superoxide in vivo accelerates age-associated muscle atrophy through mitochondrial dysfunction and neuromuscular junction degeneration. FASEB J 2010;24:1376–1390.
19. Delbono O. Neural control of aging skeletal muscle. Aging Cell 2003;2:21–29.
20. Fulle S, Protasi F, Di Tano G, Pietrangelo T, Beltramin A, Boncompagni S, et al. The contribution of reactive oxygen species to sarcopenia and muscle ageing. Exp Gerontol 2004;39:17–24.
21. Ibebunjo C, Chick JM, Kendall T, Eash JK, Li C, Zhang Y, et al. Genomic and proteomic profiling reveals reduced mitochondrial function and disruption of the neuromuscular junction driving rat sarcopenia. Mol Cell Biol 2013;33:194–212.
22. Deschenes MR, Roby MA, Eason MK, Harris MB. Remodeling of the neuromuscular junction precedes sarcopenia related alterations in myofibers. Exp Gerontol 2010;45:389–393.
23. Joseph AM, Adhihetty PJ, Buford TW, Wohlgemuth SE, Lees HA, Nguyen LM, et al. The impact of aging on mitochondrial function and biogenesis pathways in skeletal muscle of sedentary high- and low-functioning elderly individuals. Aging Cell 2012;11:801–809.
24. Peterson CM, Johannsen DL, Ravussin E. Skeletal muscle mitochondria and aging: a review. J Aging Res 2012;2012:194821. doi:10.1155/2012/194821.
25. Hiona A, Leeuwenburgh C. The role of mitochondrial DNA mutations in aging and sarcopenia: implications for the mitochondrial vicious cycle theory of aging. Exp Gerontol 2008;43:24–33.
26. Coggan AR, Spina RJ, King DS, Rogers MA, Brown M, Nemeth PM, et al. Histochemical and enzymatic comparison of the gastrocnemius muscle of young and elderly men and women. J Gerontol 1992;47:B71–B76.
27. Andersen JL. Muscle fibre type adaptation in the elderly human muscle. Scand J Med Sci Sports 2003;13:40–47.
28. Holloszy JO, Chen M, Cartee GD, Young JC. Skeletal muscle atrophy in old rats: differential changes in the three fiber types. Mech Ageing Dev 1991;60:199–213.
29. Larsson L, Biral D, Campione M, Schiaffino S. An age-related type IIB to IIX myosin heavy chain switching in rat skeletal muscle. Acta Physiol Scand 1993;147:227–234.
30. Lexell J. Human aging, muscle mass, and fiber type composition. J Gerontol A Biol Sci Med Sci 1995;50:11–16.
31. Ciciliot S, Rossi AC, Dyar KA, Blaauw B, Schiaffino S. Muscle type and fiber type specificity in muscle wasting. Int J Biochem Cell Biol 2013;45:2191–2199.
32. Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2000;86:580–588.
33. Chaitman BR. Efficacy and safety of a metabolic modulator drug in chronic stable angina: review of evidence from clinical trials. J Cardiovasc Pharmacol Ther 2004;9:S47–S64.
34. Lopaschuk GD, Barr R, Thomas PD, Dyck JR. Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme a thiolase. Circ Res 2003;93:e33–e37.
35. Vitale C, Marazzi G, Pelliccia F, Volterrani M, Cerquetani E, Spoletini I, et al. Trimetazidine improves exercise performance in patients with peripheral arterial disease. Pharmacol Res 2011;63:278–283.
36. Monti LD, Setola E, Fragasso G, Camisasca RP, Lucotti P, Galluccio E, et al. Metabolic and endothelial effects of trimetazidine on forearm skeletal muscle in patients with type 2 diabetes and ischemic cardiomyopathy. Am J Physiol Endocrinol Metab 2006;290:E54–E59.
37. Ferraro E, Giammarioli AM, Caldarola S, Lista P, Feraco A, Tinari A, et al. The metabolic modulator trimetazidine triggers autophagy and counteracts stress-induced atrophy in skeletal muscle myotubes. FEBS J 2013;280:5094–5108.
38. Penna F, Bonetto A, Muscaritoli M, Costamagna D, Minero VG, Bonelli G, et al. Muscle atrophy in experimental cancer cachexia: is the IGF-1 signaling pathway involved? Int J Cancer 2010;127:1706–1717.
39. Apolloni S, Amadio S, Montilli C, Volonte C, D'Ambrosi N. Ablation of P2X7 receptor exacerbates gliosis and motoneuron death in the SOD1-G93A mouse model of amyotrophic lateral sclerosis. Hum Mol Genet 2013;22:4102–4116.
40. Altamirano F, Valladares D, Henriquez-Olguin C, Casas M, Lopez JR, Allen PD, et al. Nifedipine treatment reduces resting calcium concentration, oxidative and apoptotic gene expression, and improves muscle function in dystrophic mdx mice. PLoS One 2013;8e81222. doi:10.1371/journal.pone.0081222.
41. Kaja S, van de Ven RC, van Dijk JG, Verschuuren JJ, Arahata K, Frants RR, et al. Severely impaired neuromuscular synaptic transmission causes muscle weakness in the Cacna1a-mutant mouse rolling Nagoya. Eur J Neurosci 2007;25:2009–2020.
42. Deacon RM. Measuring the strength of mice. J Visual Exp: JoVE 2013;76. doi:10.3791/2610.
43. Cosper PF, Leinwand LA. Myosin heavy chain is not selectively decreased in murine cancer cachexia. Int J Cancer 2012;130:2722–2727.
44. Toth MJ, Miller MS, Callahan DM, Sweeny AP, Nunez I, Grunberg SM, et al. Molecular mechanisms underlying skeletal muscle weakness in human cancer: reduced myosin-actin cross-bridge formation and kinetics. J Appl Physiol (1985) 2013;114:858–868.
45. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 2012;9:671–675.
46. Campbell MJ, McComas AJ, Petito F. Physiological changes in ageing muscles. J Neurol Neurosurg Psychiatry 1973;36:174–182.
47. Zhang C, Gao Y. Effects of aging on the lateral transmission of force in rat skeletal muscle. J Biomech 2014;47:944–948.
48. Wilson JM, Loenneke JP, Jo E, Wilson GJ, Zourdos MC, Kim JS. The effects of endurance, strength, and power training on muscle fiber type shifting. Journal Strength Condition Res / National Strength Condition Assoc 2012;26:1724–1729.
49. Gundersen K. Excitation-transcription coupling in skeletal muscle: the molecular pathways of exercise. Biol Rev Camb Philos Soc 2011;86:564–600.
50. Ferraro E, Giammarioli AM, Chiandotto S, Spoletini I, Rosano G. Exercise-induced skeletal muscle remodeling and metabolic adaptation: redox signaling and role of autophagy. Antioxid Redox Signal 2014;21:154–176.